Ligand Pharmaceuticals (LGND) EBIT Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 89.72% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 44.54% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -26.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -18.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 44.34% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 81.27% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 85.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.01% |
| Mar 31, 2026 | 6.93% |
| Dec 31, 2025 | 39.05% |
| Sep 30, 2025 | 64.50% |
| Jun 30, 2025 | -0.85% |
| Mar 31, 2025 | -166.74% |
| Dec 31, 2024 | -31.15% |
| Sep 30, 2024 | -41.51% |
| Jun 30, 2024 | -34.21% |
| Mar 31, 2024 | -14.11% |
| Dec 31, 2023 | -29.00% |
| Sep 30, 2023 | -6.35% |
| Jun 30, 2023 | -31.60% |
| Mar 31, 2023 | 55.36% |
| Dec 31, 2022 | -25.46% |
| Sep 30, 2022 | 63.77% |
| Jun 30, 2022 | 60.02% |
| Mar 31, 2022 | -86.28% |
| Dec 31, 2021 | 4.37% |
| Sep 30, 2021 | -12.40% |